By now, most investors have become well acquainted with volatility as it pertains to stocks to start 2016 and that word is certainly applicable to biotechnology stocks and exchange traded funds. Over the past month, three of the 13 worst-performing non-leveraged ETFs are biotech funds, a statistic that is made even more damning when considering januiary is usually a seasonally strong month for the biotech space.
Although biotech ETFs have sputtered to start the new year, investors are still displaying an affinity for the likes of the iShares Nasdaq Biotechnology ETF (NASDAQ: IBB) and the SPDR S&P Biotech ETF (NYSE: XBI), the ...
/www.benzinga.com/general/biotech/16/01/6161734/even-with-volatility-investors-love-biotech-etfs alt=Even With Volatility, Investors Love Biotech ETFs>Full story available on Benzinga.com
More...